drugset / Trial / NCT06585449
A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
Timeline
- Start
- 2024-10-14
- Primary completion
- 2028-07-05
- Completion
- 2028-07-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALN-HTT02 | Unknown | — | Intrathecal |